Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)
Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)

NCT05658497

RecruitingN/A

Sponsor: Biogen

Conditions: Multiple Sclerosis

Interventions: Diroximel Fumarate, Avonex, Tysabri, Dimethyl Fumarate

Countries: United States, Australia, Germany, Ireland, Spain, Switzerland, United Kingdom

The primary objectives of the study are to estimate the risk of major congenital malformations (MCMs) in infants born to women with multiple sclerosis (MS) who were exposed to diroximel fumarate (DRF) at any time from 2 weeks after the first day of their last menstrual period (LMP) up through the first trimester of pregnancy and to comparatively evaluate pregnancy outcomes with MCMs in women with MS who were exposed to DRF at any time from 2 weeks after the first day of their LMP through the first trimester of pregnancy with the following: i) women with MS who were unexposed to disease modifying therapies (DMTs) and, ii) women with MS who were exposed to other DMTs (e.g., Avonex and Tysabri Pregnancy Registries). The secondary objective of the study is to evaluate pregnancy outcomes in women with DRF exposure at any time from 2 weeks after the first day of their LMP through the end of pregnancy compared with the following: i) women with MS who were unexposed to DMTs, ii) women with dimethyl fumarate (DMF) exposure, iii) women with MS who were exposed to other DMTs (e.g., Avonex and Tysabri Pregnancy Registries), and iv) women without MS (e.g., women from external, general population comparators).

Eligibility overview

Sex: FEMALE

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria
Key Inclusion Criteria:

* Participant must have a diagnosis of MS
* Documentation that the participant was one of the following:

  1. exposed to DRF at any time from 2 weeks after the first day of their LMP (i.e., conception date) up through any time during pregnancy. (If exact exposure dates are unknown, the reporter must be able to specify or estimate trimester of exposure).
  2. unexposed to any DMT during pregnancy, defined as having never received DMT therapy; discontinued treatment with DRF at least 1 day before 2 weeks after the first day of their LMP (i.e., conception date); or discontinued a non Registry-specified MS DMT more than 5 times its half-life prior to 2 weeks after the first day of their LMP (i.e., conception date)
* Participants with knowledge of the outcome of the pregnancy (e.g., pregnancy loss or live birth)

Key Exclusion Criteria:

\- None

NOTE: Other protocol defined Inclusion criteria may apply
Locations (8)
  • Aurora, Colorado, United States
  • Durham, North Carolina, United States
  • Heidelberg, Australia
  • Bochum, North Rhine-Westphalia, Germany
  • Dublin, Ireland
  • Madrid, Spain
  • Bern, Switzerland
  • Salford, Greater Manchester, United Kingdom